121 related articles for article (PubMed ID: 34618220)
1. Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?
Jin YN; Cao HJ; Gong XH; Zhang WJ; Marks T; Yao JJ; Xia LP
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2569-2579. PubMed ID: 34618220
[TBL] [Abstract][Full Text] [Related]
2. Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study.
Jin YN; Qiang MY; Liu MM; Cheng ZB; Zhang WJ; Ryan I; Marks T; Yao JJ; Xia LP
Cancer Cell Int; 2021 Nov; 21(1):604. PubMed ID: 34772421
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in elderly patients with stage III-IVa nasopharyngeal carcinoma: A real-world study based on medical comorbidities.
Jin YN; Xiao ZW; Yao W; Yu J; Zhang WJ; Marks T; Zhang HY; Yao JJ; Xia LP
Head Neck; 2024 Feb; ():. PubMed ID: 38366693
[TBL] [Abstract][Full Text] [Related]
4. Development of a web-based prognostic model to quantify the survival benefit of cumulative cisplatin dose during concurrent chemoradiotherapy in childhood nasopharyngeal carcinoma.
Jin YN; Yang QQ; Li ZQ; Ou XQ; Zhang WJ; Marks T; Yao JJ; Xia LP
Radiother Oncol; 2022 Jan; 166():118-125. PubMed ID: 34838885
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study.
Jin YN; Ruan ZH; Cao WW; Yang L; Yao W; Pei XF; Zhang WJ; Marks T; Yao JJ; Xia LP
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11929-11940. PubMed ID: 37418058
[TBL] [Abstract][Full Text] [Related]
6. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
[TBL] [Abstract][Full Text] [Related]
7. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
[TBL] [Abstract][Full Text] [Related]
8. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
10. Optimal cumulative cisplatin dose during concurrent chemoradiotherapy among children and adolescents with locoregionally advanced nasopharyngeal carcinoma: A real-world data study.
Jin YN; Yao JJ; You YF; Cao HJ; Li ZZ; Dai DL; Zhang WJ; Marks T; Zhang B; Xia LP
Radiother Oncol; 2021 Aug; 161():83-91. PubMed ID: 34116076
[TBL] [Abstract][Full Text] [Related]
11. Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Luo WJ; Zou WQ; Liang SB; Chen L; Zhou GQ; Peng H; Li WF; Liu X; Sun Y; Lin AH; Ma J; Mao YP
Radiother Oncol; 2021 Feb; 155():56-64. PubMed ID: 33039423
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
14. Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up.
Wu SY; Wu YH; Yang MW; Hsueh WT; Hsiao JR; Tsai ST; Chang KY; Chang JS; Yen CJ
BMC Cancer; 2014 Oct; 14():787. PubMed ID: 25351202
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Li Y; Tang QN; Sun XS; Liang YJ; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
J Natl Compr Canc Netw; 2019 Jun; 17(6):703-710. PubMed ID: 31200353
[TBL] [Abstract][Full Text] [Related]
16. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
Xu C; Chen YP; Liu X; Li WF; Chen L; Mao YP; Zhang Y; Guo R; Zhou GQ; Tang LL; Lin AH; Sun Y; Ma J
Oral Oncol; 2017 Jun; 69():99-107. PubMed ID: 28559028
[TBL] [Abstract][Full Text] [Related]
17. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
20. MRI-Based Deep-Learning Model for Distant Metastasis-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang L; Wu X; Liu J; Zhang B; Mo X; Chen Q; Fang J; Wang F; Li M; Chen Z; Liu S; Chen L; You J; Jin Z; Tang B; Dong D; Zhang S
J Magn Reson Imaging; 2021 Jan; 53(1):167-178. PubMed ID: 32776391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
